MX2022007332A - Sistema terapeutico transmucoso que contiene agomelatina. - Google Patents

Sistema terapeutico transmucoso que contiene agomelatina.

Info

Publication number
MX2022007332A
MX2022007332A MX2022007332A MX2022007332A MX2022007332A MX 2022007332 A MX2022007332 A MX 2022007332A MX 2022007332 A MX2022007332 A MX 2022007332A MX 2022007332 A MX2022007332 A MX 2022007332A MX 2022007332 A MX2022007332 A MX 2022007332A
Authority
MX
Mexico
Prior art keywords
agomelatine
transmucosal
transmucosal therapeutic
system containing
therapeutic system
Prior art date
Application number
MX2022007332A
Other languages
English (en)
Inventor
Patrick Mohr
René Rietscher
René EIFLER
Olga Bourquain
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2022007332A publication Critical patent/MX2022007332A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a sistemas terapéuticos transmucosales para la administración transmucosal de agomelatina que comprende una estructura de capa mucoadhesiva que comprende una cantidad terapéuticamente efectiva de agomelatina, tales sistemas terapéuticos transmucosales de agomelatina para uso en un método de tratamiento, un método de tratamiento que comprende aplicar tales sistemas terapéuticos transmucosales de agomelatina, y procesos de manufactura de tales sistemas terapéuticos transmucosales.
MX2022007332A 2019-12-20 2020-10-02 Sistema terapeutico transmucoso que contiene agomelatina. MX2022007332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19218592 2019-12-20
PCT/EP2020/077736 WO2020260726A1 (en) 2019-12-20 2020-10-02 Transmucosal therapeutic system containing agomelatine

Publications (1)

Publication Number Publication Date
MX2022007332A true MX2022007332A (es) 2022-07-13

Family

ID=69411121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007332A MX2022007332A (es) 2019-12-20 2020-10-02 Sistema terapeutico transmucoso que contiene agomelatina.

Country Status (10)

Country Link
US (1) US20220401389A1 (es)
EP (1) EP4076381A1 (es)
JP (1) JP2023506537A (es)
KR (1) KR20220118455A (es)
CN (2) CN113597303B (es)
AU (1) AU2020302262A1 (es)
BR (1) BR112022012139A2 (es)
CA (1) CA3162225A1 (es)
MX (1) MX2022007332A (es)
WO (1) WO2020260726A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023170184A1 (en) * 2022-03-11 2023-09-14 Lts Lohmann Therapie-Systeme Ag Transmucosal therapeutic system containing a macrolide immunosuppressant
CN116832015A (zh) * 2023-08-21 2023-10-03 力品药业(厦门)股份有限公司 一种经口腔黏膜给药的阿戈美拉汀膜剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769500B2 (en) * 1996-10-18 2004-01-29 Arius Two, Inc. Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
CN102579415B (zh) * 2011-01-14 2014-11-05 成都康弘药业集团股份有限公司 一种含有阿戈美拉汀的口腔粘膜或舌下给药的药物组合物
EP3154522A1 (en) * 2014-06-10 2017-04-19 Laboratorio Chimico Internazionale S.p.A. Agomelatine in solution adsorbates and compositions
WO2016109483A1 (en) * 2014-12-30 2016-07-07 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for agomelatine

Also Published As

Publication number Publication date
BR112022012139A2 (pt) 2022-10-04
CA3162225A1 (en) 2020-12-30
CN113597303B (zh) 2022-11-18
WO2020260726A1 (en) 2020-12-30
CN113597303A (zh) 2021-11-02
JP2023506537A (ja) 2023-02-16
KR20220118455A (ko) 2022-08-25
EP4076381A1 (en) 2022-10-26
US20220401389A1 (en) 2022-12-22
AU2020302262A1 (en) 2022-06-02
CN115737607A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
MX2022007331A (es) Sistema terapéutico transmucosal que contiene agomelatina.
MX2019007391A (es) Sistema terapeutico transdermico que contiene asenapina.
MX2022007332A (es) Sistema terapeutico transmucoso que contiene agomelatina.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
EA202091640A1 (ru) Способы лечения опосредованного il-6 воспаления без иммунодепрессии
EP4249431A3 (en) Compositions and methods for treating diseases or disorders using extended release nitric oxide releasing solutions
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
WO2018102687A3 (en) Combination therapy for treating cancer
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2020011295A (es) Tratamiento de dermatitis atopica.
MX2020013166A (es) Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca.
BR112022012111A2 (pt) Sistema terapêutico transdérmico contendo agomelatina
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2020014286A (es) Sistema terapeutico transdermico que contiene asenapina.
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
IL283324A (en) A process for the production of pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors and their use in the treatment of respiratory disorders
MX2019014784A (es) Tratamiento para la migra?a.
SG11202106205YA (en) Transdermal system for the delivery of abaloparatide and method of use
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain